IGC
IGC Pharma, Inc.
$0.28
+0.01 (+3.70%)
At close · Jul 2
Going-concern doubt
— cleared May 15, 2026
The latest filing states the doubt was alleviated.
“raise substantial doubt about its ability to continue as a going concern. The Company is currently in the clinical trial stage and has not yet achieved profitability. The Company expects to continue to incur significant operating and net losses, as well as negative cash flow from operations, in the near future.”View the 10-Q filed May 15, 2026
Market Cap
$28.12M
Shares
100,091,317
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Equity Offering (ATM) Programs
| Program Established | Capacity | Remaining | As of | Runs Through | Source |
|---|---|---|---|---|---|
| 2023-10-27 | $60,000,000 | $4,700,000 | 2026-03-31 | — | 10-Q , filed 2026-05-15 |